📄 Official sourceAdvisory
Stanford Medicine
Stanford Medicine has launched an expanded access program (EAP) for daraxonrasib, an investigational drug that has shown promising results in treating metastatic pancreatic cancer. The disease, which has a five-year survival rate of just 3%, now sees hope as the drug has doubled median survival times in trials. While awaiting FDA approval, Stanford is offering the drug to eligible patients, marking a significant move to make advanced treatments available outside clinical trials.
This initiative builds on years of research into previously "undruggable" pathways in pancreatic cancer. The program, in collaboration with Revolution Medicines, positions Stanford as a leader in accelerating access to transformative therapies and could influence how other institutions approach expanded access programs.
Investment implication: This marks the second major development in Stanford's oncology research since July 2, signaling its growing influence in translational medicine. For you, this highlights how academic institutions are increasingly driving early-stage medical innovation, potentially reshaping funding and partnership opportunities in oncology.